¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ABO antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® ABO erythroblastosis ÇÑ±Û ÀÌ¿¡ºñ¿À Àû¸ð±¸Áõ
¼³¸í   
  ÀûÇ÷±¸Ç¥¸é¿¡ Á¸ÀçÇϴ ¿©·¯ °¡Áö Ç׿øÁß¿¡¼­ A, BÇ׿øÀÌ Á¸ÀçÇÑ´Ù. À̰ÍÀ¸·Î Ç÷¾×ÇüÀ» Á¤Çϴ ¹æ¹ýÀÌ ABOÇü Ç÷¾×ÇüÀÌ´Ù. ÀÌ Ç÷¾×ÇüÀº ¸¸¾à AÇ׿øÀ» °¡Áö°í ÀÖÀ¸¸é AÇü, BÇ׿øÀ» °¡Áö°í ÀÖÀ¸¸é BÇü, ±×¸®°í A, B ¸ðµÎ¸¦ °¡Áö¸é ABÇü, ¾Æ¹« °Íµµ °¡Áö°í ÀÖÁö ¾ÊÀ¸¸é OÇüÀ¸·Î ºÐ·ù¸¦ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î AÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô´Â BÇ׿ø¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇϰí BÇü Ç÷¾×ÇüÀ» °¡Áø ÀÚ¿¡°Ô´Â AÇ׿ø¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÑ´Ù. ABÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô´Â A, B¿¡ ´ëÇÑ Ç×ü°¡ ¸ðµÎ Á¸ÀçÇÏÁö ¾Ê°í, OÇü Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô´Â A, B¿¡ ´ëÇÑ µÎ°¡Áö Ç×ü°¡ ¸ðµÎ Á¸ÀçÇÑ´Ù. ÀÌ ABO Àû¸ð±¸ÁõÀº ¾î¸Ó´Ï¿Í Å¾ƻçÀÌÀÇ ÀÌ ABO Ç÷¾×ÇüÀÇ ºÎÀûÇÕÀ¸·Î ÀÎÇØ¼­ »ý±â´Â °ÍÀ¸·Î À̹̠Á¤»óÀûÀ¸·Î Á¸ÀçÇϴ Ç×ü°¡ Å¹ÝÀ» ÅëÇØ¼­ Å¾ƿ¡°Ô °Ç³Ê°¬À» °æ¿ì¿¡ »ý±ä´Ù. Áï ¾î¸Ó´Ï°¡ OÇüÀÇ Ç÷¾×ÇüÀ» °¡Á³À» °æ¿ì¿¡ ¾î¸Ó´Ï´Â Á¤»óÀûÀ¸·Î A, BÀÇ µÎ °¡Áö Ç׿ø¿¡ ´ëÇØ¼­ ¸ðµÎ Ç×ü¸¦ °¡Áö°í ÀÖ´Ù. ±×·±µ¥ Å¾ư¡ AÇüÀΠ°æ¿ì¿¡ ¾î¸Ó´Ï¿¡ Á¸ÀçÇϴ A¿¡ ´ëÇÑ Ç×ü°¡ Å¹ÝÀ» ÅëÇØ¼­ °Ç³Ê¿ÔÀ» °æ¿ì¿¡ À̰Ͱú Å¾ÆÀÇ ÀûÇ÷±¸¿¡ ºÎÂøÀÌ µÇ°í Ç×ü°¡ ºÎÂøÀÌ µÈ ÀûÇ÷±¸´Â ¿ª½Ã ÆÄ±«°¡ µÈ´Ù. ´ëºÎºÐÀÇ °æ¿ì ¾î¸Ó´Ï°¡ OÇü, ¾Æ±â°¡ AÇü, BÇüÀÏ ¶§ ÀϾ´Ù. ABOÀû¾Æ±¸ÁõÀÇ Áõ¼¼´Â Rh Àû¸ð±¸Áõº¸´Ù °¡º­¿ì³ª ÈξÀ ´õ ºó¹øÀÌ ÀϾ´Ù. ±×·¯³ª Rh Àû¾Æ±¸ÁõÀº Ã¹¹øÂ° ¾ÆÀÌ¿¡¼­ Àû°Ô »ý±â°í ´ëºÎºÐÀÇ °æ¿ì µÎ¹øÂ° ¾ÆÀÌ¿¡¼­ ¸¹ÀÌ »ý±â´Âµ¥ ºñÇÏ¿© ABO Àû¸ð±¸ÁõÀº ¾à 50%°¡ Ã¹ ¾Æ±â¿¡¼­ º¼ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T antigens
    TÇ׿ø
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • ABO typing
    ABOÇ÷¾×Çü°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO typing
    ¿¡À̺ñ¿ÀÇ÷¾×Çü°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO typing
    ¿¡À̺ñ¿ÀÇ÷¾×Çü°Ë»ç
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • ABO blood group
    ABO Ç÷¾×Çü.
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO discrepancy
    ABO ºÒÀÏÄ¡
  • ABO hemolytic disease
    ABO ¿ëÇ÷¼º Áúȯ(¡­éÁúìàõ òðü´)
  • ABO hemolytic disease of the newborn
    ½Å»ý¾Æ ABO ¿ëÇ÷¼ºÁúȯ
  • ABO incompatibility
    ABOºÎÀûÇÕ.
  • ABO locus
    ABO ÁÂÀ§(¡­ñ¨êÈ)
  • ABO typing
    ABO ±³Â÷°Ë»ç
  • ABO typing
    ABO Çüº°<Ç÷¾×Çü>°Ë»ç
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Yka antigens
    YKa Ç׿ø
  • granulocyte-erythrocyte antigens
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigens
    °ú¸³±¸´Ü±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • discrepancy in ABO blood group
    ABO Ç÷¾×ÇüºÒÀÏÄ¡
  • granulocyte-erythrocyte antigens
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigens
    °ú¸³±¸´Ü±¸Ç׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • histocompatibility antigens
    Á¶Á÷ÀûÇÕ Ç׿ø
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • carcinoembryonic antigens
    ¾Ï¹è¾ÆÇ׿ø(äßÛÏä´ù÷ê«)
  • class II MHC antigens
    "Á¦ 11 ·ù(×¾) MHC Ç׿ø(ù÷ê«), (ÔÒ) 1-region-associated antigens"
  • Epa antigens
    EPa Ç׿ø(ù÷ê«)
  • H-2 antigens
    H-2 Ç׿ø(ù÷ê«)
  • HLA antigens
    HLA Ç׿ø (ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ABO Three Main Blood Types
ABO abortion; absent bed occupancy; American Board of Orthodontists; blood group system consisting of gr...
OAB ABO blood group; old age benefits
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
Anti-ENA Anti-Extractable Nuclear Antigens
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HLA Histocompatibility Antigens
Ipa Invasion plasmid antigens
MHC Major histocompatibility antigens
MAA Melanoma-associated antigens
MiHA Minor histocompatibility antigens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • ABO system
    ABO Çü, ABO °èÅë
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
ABO antigens <haematology, immunology> A system of genetically determined antigens (proteins) located on the surface of the erythrocyte.
The presence of these specific antigens gives a blood its unique properties. Because of the antigen differences existing between individuals, blood groups are significant in blood transfusions, maternal-foetal incompatibilities (erythroblastosis foetalis), tissue and organ transplantation.
(27 Sep 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
ABO blood group <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells.
According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom.
Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood.
Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors.
And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction.
(04 Jul 1999)
ABO haemolytic disease of the newborn Erythroblastosis foetalis due to maternal-foetal incompatibility with respect to an antigen of the ABO blood group; the foetus possesses A or B antigen which is lacking in the mother, and the mother produces immune antibody which causes haemolysis of foetal erythrocytes.
(05 Mar 2000)
ABO incompatibility <haematology> A type of blood incompatibility, found rarely. Transfusion reactions may occur as a result of such incompatibility.
(27 Sep 1997)
Am antigens Allotypic determinants (antigens) on human immunoglobulin alpha heavy chains.
(05 Mar 2000)
antigens Substances which are capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibodies or specifically sensitised T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulates, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (epitopes) combines with antibody or a specific receptor on a lymphocyte.
(12 Dec 1998)
antigens, archaeal Substances of archaeal origin that have antigenic activity.
(12 Dec 1998)
antigens, bacterial Substances elaborated by bacteria that have antigenic activity.
(12 Dec 1998)
antigens, CD <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
antigens, CD1 <immunology> Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC class I and their function has been postulated as similar also. Cd1 antigens are highly specific markers for human langerhans cells.
(12 Dec 1998)
antigens, CD11 <immunology> A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (antigens, CD18). The three resulting leukocyte-adhesion molecules (receptors, leukocyte adhesion) are lymphocyte function-associated antigen-1, macrophage-1 antigen, and antigen, p150,95.
(12 Dec 1998)
antigens, CD13 <enzyme, immunology> Glycoproteins expressed on human granulocyte-monocyte progenitor colony forming units (cfu-gm) and their more differentiated progeny. The enzymes are also found in a large number of tissues, often associated with membranes.
Registry number: EC 3.4.11.2
(12 Dec 1998)
antigens, CD14 <immunology> Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (lps) and lps-binding protein.
(12 Dec 1998)
antigens, CD15 <immunology> Carbohydrate antigen which is accumulated in various human cancer tissues and secreted into the blood stream. The carbohydrate moiety can be further modified with fucose or sialic acid. Monoclonal antibodies have been determined which can discriminate each subgroup of this antigen in the sera of cancer patients. Sialyl ssea-1 antigen is particularly elevated in the sera of patients with a variety of tumours.
(12 Dec 1998)
antigens, CD18 <immunology> Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (receptors, leukocyte-adhesion). A defect in the gene encoding CD18 causes leukocyte-adhesion deficiency syndrome.
(12 Dec 1998)
antigens, CD19 <immunology> Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO
    Ç÷¾×Á¶Á÷ABOºÐ·ù¹ý
  • Abo-o, ab-o
    =ABORIGINAL
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á